Medical Information
|
Non-US Health Care Professionals
Account Settings
Sign Out
Sign In | Create Account
  • Diabetes Home
  •  Icon
    Products
    Diabetes Treatments
     Icon
    Professional Resources
    Product Resources Library
    Insulin & Type 1 Diabetes
    Medical Information
    |
    Non-US Health Care Professionals
  • Sample Requests
  •  Icon
    Diabetes Education
    Clinical Education Library
    Diabetes Risk Assessment Tool
    Diabetes & Cardiovascular Disease
     Icon
    Treatment Guidelines
    ADA Standards of Care
    AACE Diabetes Guidelines
     Icon
    Additional Resources
    Organizations & Conferences
    Medical Information
    |
    Non-US Health Care Professionals
  •  Icon
    Product Education
    Product Education Materials
    Pen Device Training Center
     Icon
    Disease Education
    Disease Education Library
     Icon
    Prescription Savings & Coverage
    Savings Cards
    Insurance Coverage
    Affordability Resources
    ICD-10 Codes for Diabetes
     Icon
    Support Program
    Diabetes Management
    Cardiovascular Risk Management
    Medical Information
    |
    Non-US Health Care Professionals
Diabetes
Ozempic® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg logo
  • Ozempic® Overview Mechanism of Action FAQs
  • Ozempic® and A1C Ozempic® and Weight Special Populations Safety Profile
  • T2D & CVD
  • T2D & CKD
  • Dosing and Prescribing Ozempic® Pen
  • Disease State Information Cost and Coverage HCP Resources Patient Resources For Pharmacists Samples
Prescribing Information | Important Safety Information | Patient Site

Explore Therapeutic Areas

Diabetes Icon
Diabetes
Our broad treatment portfolio supports individualized patient care.
Obesity Icon
Obesity
Our treatments are part of a comprehensive approach to weight-loss management.
Growth-Related Disorders Icon
Growth-Related Disorders
Our products help children with a range of growth-related disorders and adults with growth hormone deficiency.
Rare Bleeding Disorders Icon
Rare Bleeding Disorders
Our commitment to patients with hemophilia and rare bleeding disorders is reflected in our broad therapy portfolio.
Rare Renal Disorders Icon
Rare Renal Disorders
Our treatment helps patients with the rare genetic disorder primary hyperoxaluria type 1 (PH1).
Medical Information
|
Non-US Health Care Professionals
  • Diabetes Home
  • Sample Requests
Account Settings
Sign Out
Sign In | Create Account
Update your account
Medical Information
|
Non-US Health Care Professionals

Explore the Hub

Products
Samples
Patient Savings
Contact

Explore Therapeutic Areas

Diabetes
Diabetes
Obesity
Obesity
Growth-Related Disorders
Growth-Related Disorders
Rare Bleeding Disorders
Rare Bleeding Disorders
Rare Renal Disorders
Rare Renal Disorders
Claim your personalized professional hub
What can novoMEDLINK™ do for you? With your account you can discover professional news, order samples, get supply updates, browse patient support materials, and much more.
Personalize your novoMEDLINK™ experience
Ready to further optimize your content recommendations and resource suggestions? Head to your account page to edit your settings.
Account Settings
Sign Out
Sign In | Create Account
Update your account
  • Products
    Samples
    Patient Savings
    Contact
    Diabetes
    Diabetes
    Obesity
    Obesity
    Growth-Related Disorders
    Growth-Related Disorders
    Rare Bleeding Disorders
    Rare Bleeding Disorders
    Rare Renal Disorders
    Rare Renal Disorders
Claim your personalized
professional hub
Personalize your novoMEDLINK™ experience
Account Settings
Sign Out
Sign In | Create Account
Update your account
Medical Information
|
Non-US Health Care Professionals
  • Diabetes Home
  •  Icon
    Products
    Diabetes Treatments
     Icon
    Professional Resources
    Product Resources Library
    Insulin & Type 1 Diabetes
  • Sample Requests
  •  Icon
    Diabetes Education
    Clinical Education Library
    Diabetes Risk Assessment Tool
    Diabetes & Cardiovascular Disease
     Icon
    Treatment Guidelines
    ADA Standards of Care
    AACE Diabetes Guidelines
     Icon
    Additional Resources
    Organizations & Conferences
  •  Icon
    Product Education
    Product Education Materials
    Pen Device Training Center
     Icon
    Disease Education
    Disease Education Library
     Icon
    Prescription Savings & Coverage
    Savings Cards
    Insurance Coverage
    Affordability Resources
    ICD-10 Codes for Diabetes
     Icon
    Support Program
    Diabetes Management
    Cardiovascular Risk Management
Medical Information
|
Non-US Health Care Professionals

Explore Current Therapy Area

Diabetes Home
Products
Diabetes Treatments
Professional Resources
Product Resources Library
Insulin & Type 1 Diabetes
Make a Request
Diabetes Education
Clinical Education Library
Diabetes Risk Assessment Tool
Diabetes & Cardiovascular Disease
Treatment Guidelines
ADA Standards of Care
AACE Diabetes Guidelines
Additional Resources
Organizations & Conferences
Product Education
Product Education Materials
Pen Device Training Center
Disease Education
Disease Education Library
Prescription Savings & Coverage
Savings Cards
Insurance Coverage
Affordability Resources
ICD-10 Codes for Diabetes
Support Program
Diabetes Management
Cardiovascular Risk Management
Diabetes
Diabetes
Obesity
Obesity
Growth-Related Disorders
Growth-Related Disorders
Rare Bleeding Disorders
Rare Bleeding Disorders
Rare Renal Disorders
Rare Renal Disorders
Medical Information
|
Non-US Health Care Professionals
Claim your personalized professional hub
What can novoMEDLINK™ do for you? With your account you can discover professional news, order samples, get supply updates, browse patient support materials, and much more.
Personalize your novoMEDLINK™ experience
Ready to further optimize your content recommendations and resource suggestions? Head to your account page to edit your settings.
Account Settings
Sign Out
Sign In | Create Account
Update your account

Explore Current Therapy Area

  • Diabetes Home
  •  Icon
    Products
    Diabetes Treatments
     Icon
    Professional Resources
    Product Resources Library
    Insulin & Type 1 Diabetes
  • Sample Requests
  •  Icon
    Diabetes Education
    Clinical Education Library
    Diabetes Risk Assessment Tool
    Diabetes & Cardiovascular Disease
     Icon
    Treatment Guidelines
    ADA Standards of Care
    AACE Diabetes Guidelines
     Icon
    Additional Resources
    Organizations & Conferences
  •  Icon
    Product Education
    Product Education Materials
    Pen Device Training Center
     Icon
    Disease Education
    Disease Education Library
     Icon
    Prescription Savings & Coverage
    Savings Cards
    Insurance Coverage
    Affordability Resources
    ICD-10 Codes for Diabetes
     Icon
    Support Program
    Diabetes Management
    Cardiovascular Risk Management
  • Diabetes
    Diabetes
    Obesity
    Obesity
    Growth-Related Disorders
    Growth-Related Disorders
    Rare Bleeding Disorders
    Rare Bleeding Disorders
    Rare Renal Disorders
    Rare Renal Disorders

Claim your personalized
professional hub

Personalize your novoMEDLINK™ experience

Account Settings
Sign Out
Sign In | Create Account
Update your account
Medical Information
|
Non-US Health Care Professionals
  • Ozempic® Overview
    Mechanism of Action
    FAQs
  • Ozempic® and A1C
    Ozempic® and Weight
    Special Populations
    Safety Profile
  • T2D & CVD
  • T2D & CKD
  • Dosing and Prescribing
    Ozempic® Pen
  • Disease State Information
    Cost and Coverage
    HCP Resources
    Patient Resources
    For Pharmacists
    Samples
Prescribing Information | Important Safety Information | Patient Site
Medical Information
|
Non-US Health Care Professionals
 |  Important Safety Information

Ozempic® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg

RYBELSUS® (semaglutide) tablets 7 mg or 14 mg

Victoza® (liraglutide) injection 1.2 mg or 1.8 mg

Xultophy® 100/3.6 (insulin degludec and liraglutide) injection 100 U/mL and 3.6 mg/mL

Fiasp® (insulin aspart) injection 100 U/mL

GlucaGen® HypoKit® (glucagon) for injection 1 mg/mL

Levemir® (insulin detemir) injection 100 U/mL

NovoLog® (insulin aspart) injection 100 U/mL

NovoLog® Mix 70/30 (insulin aspart protamine and insulin aspart) injectable suspension 100 U/mL

Tresiba® (insulin degludec) injection 100 U/mL, 200 U/mL

ZEGALOGUE® (dasiglucagon) injection 0.6 mg/ 0.6 mL

Talking to your patients about Ozempic® (semaglutide) injection

Pharmacists, patients may have questions when they pick up their prescription of Ozempic®. Here are some topics you may want to discuss with them.

See how to dispense Ozempic®

Adult patient with type 2 diabetes asking her pharmacist about her Ozempic® prescription

Actor portrayals.

What is Ozempic®?

Ozempic® is an injectable prescription medicine used:

  • For adults with type 2 diabetes, along with diet and exercise, to improve blood sugar (glucose)
  • For adults with type 2 diabetes with known heart disease, to reduce the risk of major cardiovascular events such as heart attack, stroke, or death 
  • For adults with type 2 diabetes and chronic kidney disease, to reduce the risk of kidney disease worsening, kidney failure (end-stage kidney disease), and death due to cardiovascular disease 

It is not known if Ozempic® is safe and effective for use in children.

See Section 17: Patient Counseling Information in the Prescribing Information

Three Ozempic® pens

Ozempic® once-weekly dose options for a range of patients

Gradual dose escalation designed to help patients adjust to therapy1,a

Red Ozempic® pen
Pen that delivers
0.25 mg and 0.5 mg only
Blue Ozempic® pen
Pen that delivers
1 mg only
Yellow Ozempic® pen
Pen that delivers
2 mg only

aThe starting dose of 0.25 mg is a nontherapeutic dose.

T2D=type 2 diabetes.

Gradual dose escalation to help patients adjust to therapy1

  • Administer Ozempic® once weekly on the same day each week, at any time of the day, with or without meals
  • The maximum recommended dosage is 2 mg once weekly
  • The day of weekly administration can be changed if necessary as long as the time between 2 doses is at least 2 days (>48 hours)
  • If a dose is missed, administer Ozempic® as soon as possible within 5 days after the missed dose. If more than 5 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day. In each case, patients can then resume their regular once-weekly dosing schedule
Cost and coverage page

Savings are available for eligible patients

View savings

Ozempic® is available in multi-use pens with needles included1

The Ozempic® injection is supplied as a clear, colorless solution in a prefilled, disposable, single-patient-use pen in the following packaging configurations:

Red Label


Pen that delivers doses of 0.25 mg and 0.5 mg

Contains 2 mg of Ozempic®
Delivers only the starting dose of 0.25 mg and a maintenance dose of 0.5 mg

Red label Ozempic® (semaglutide) injection Pen includes 6 needles

Includes

x6

Red label Ozempic® (semaglutide) injection Pen includes 6 needles
Red label Ozempic® (semaglutide) injection Pen includes 6 needles

Blue Label


Pen that delivers doses of 1 mg

Contains 4 mg of Ozempic®
Delivers only the maintenance dose of 1 mg

Blue label Ozempic® (semaglutide) injection pen includes 4 needles

Includes

x4

Red label Ozempic® (semaglutide) injection Pen includes 6 needles
Blue label Ozempic® (semaglutide) injection pen includes 4 needles

Yellow Label


Pen that delivers doses of 2 mg

Contains 8 mg of Ozempic®
Delivers only the maximum maintenance dose of 2 mg

Yellow label Ozempic® (semaglutide) injection pen includes 4 needles

Includes

x4

Red label Ozempic® (semaglutide) injection Pen includes 6 needles
Yellow label Ozempic® (semaglutide) injection pen includes 4 needles

Thinnest needle (32G, 4 mm) on a once-weekly GLP-1 RA included with each pen

Ozempic® Dispensing Guide
PDF
Ozempic® Dispensing Guide
A quick reference guide for details of Ozempic® pen packs, including NDC, strength, and contents.
Download
Prescribing Information | Important Safety Information

Order today

Ozempic<sup>®</sup> Demonstration Pen (0.25 mg, 0.5 mg)
Ozempic® Demonstration Pen (0.25 mg, 0.5 mg)
For demonstration and training only. Not for patients or injection into humans. Does not contain medicine. Only to be used by a health care professional. Needles are not included.
Add to order
Prescribing Information | Important Safety Information
Prescribing Information | Important Safety Information
Ozempic® Pen Instructions for Use
(3:43)
Ozempic® Pen Instructions for Use
An overview for patients on how to use the Ozempic® Pen, this easy-to-follow video illustrates how they can administer Ozempic®. You may also view illustrated step-by-step instructions.
Watch video
Prescribing Information | Important Safety Information

How to store the Ozempic® Pen1

Prior to first use

Until expiration date


Refrigerator icon

Refrigerated
36°F to 46°F (2°C to 8°C)

After first use

56 days


Room temperature storage

Room Temperature
59°F to 86°F (15°C to 30°C)

Refrigerator icon

Refrigerated
36°F to 46°F (2°C to 8°C)

How to dispense Ozempic®1

Ozempic® 0.25 mg or 0.5 mg dose
(2 mg/3 mL subcutaneous pen injector)

NDC: 0169-4181-13


Days supply:

  • Sample/initial (42 days)
  • 1-month supply (28 days)

Intent of prescription:

  • Sample or initial prescription for new starts
  • 1-month prescription for maintenance on 0.5 mg
  • For patients with T2D and CKD, increase to the recommended maintenance dose of 1 mg after at least 4 weeks on 0.5 mg

Strength: 2 mg per 3 mL (0.68 mg/mL)


Dosage form: Solution


SIG:

  • Sample or initial Rx: Inject 0.25 mg SUBQ once weekly for 4 weeks, then 0.5 mg SUBQ once weekly for 2 weeks
  • Maintenance Rx: Inject 0.5 mg SUBQ once weekly for 4 weeks

Dispense quantity: 3 mL


Dispense quantity unit of measure: mL ONLY


Needles: 6 included


Number of boxes: 1 box


Ozempic® 0.25 mg or 0.5 mg dose
(2 mg/3 mL subcutaneous pen injector)

NDC: 0169-4181-13


Days supply:
3-month supply (84 days)


Intent of prescription:

  • 3-month prescription for maintenance on 0.5 mg
  • For patients with T2D and CKD, increase to the recommended maintenance dose of 1 mg after at least 4 weeks on 0.5 mg

Strength: 2 mg per 3 mL (0.68 mg/mL)


Dosage form: Solution


SIG: Maintenance Rx: Inject 0.5 mg SUBQ once weekly for 12 weeks


Dispense quantity: 9 mL


Dispense quantity unit of measure: mL ONLY


Needles: 18 included


Number of boxes: 3 boxes


Ozempic® 1 mg dose
(4 mg/3 mL subcutaneous pen injector)

NDC: 0169-4130-13


Days supply:

  • 1-month supply (28 days)

Intent of prescription:

1-month prescription for maintenance on 1 mg


Strength: 4 mg per 3 mL (1.34 mg/mL)


Dosage form: Solution


SIG: Maintenance Rx: Inject 1 mg SUBQ once weekly for 4 weeks


Dispense quantity: 3 mL


Dispense quantity unit of measure: mL ONLY


Needles: 4 included


Number of boxes: 1 box


Ozempic® 1 mg dose
(4 mg/3 mL subcutaneous pen injector)

NDC: 0169-4130-13


Days supply:
3-month supply (84 days)


Intent of prescription:

  • 3-month prescription for maintenance on 1 mg
  • For patients with T2D and CKD, increase to the recommended maintenance dose of 1 mg

Strength: 4 mg per 3 mL (1.34 mg/mL)


Dosage form: Solution


SIG: Maintenance Rx: Inject 1 mg SUBQ once weekly for 12 weeks


Dispense quantity: 9 mL


Dispense quantity unit of measure: mL ONLY


Needles: 12 included


Number of boxes: 3 boxes


Ozempic® 2 mg dose
(8 mg/3 mL subcutaneous pen injector)

NDC: 0169-4772-12


Days supply:

  • 1-month supply (28 days)

Intent of prescription:

  • 1-month prescription for maintenance on 2 mg

Strength: 8 mg per 3 mL (2.68 mg/mL)


Dosage form: Solution


SIG: Maintenance Rx: Inject 2 mg SUBQ once weekly for 4 weeks


Dispense quantity: 3 mL


Dispense quantity unit of measure: mL ONLY


Needles: 4 included


Number of boxes: 1 box


Ozempic® 2 mg dose
(8 mg/3 mL subcutaneous pen injector)

NDC: 0169-4772-12


Days supply:
3-month supply (84 days)


Intent of prescription:
3-month prescription for maintenance on 2 mg


Strength: 8 mg per 3 mL (2.68 mg/mL)


Dosage form: Solution


SIG: Maintenance Rx: Inject 2 mg SUBQ once weekly for 12 weeks


Dispense quantity: 9 mL


Dispense quantity unit of measure: mL ONLY


Needles: 12 included


Number of boxes: 3 boxes


CKD=chronic kidney disease.

More ways to help your patients with T2D

Cost and coverage page

Check your patients' coverage and view savings offer

See details »


Free and personalized patient support is available

Free, personalized patient support is available
View support program »

Show More Show Less

Important Safety Information for Ozempic®

WARNING: RISK OF THYROID C-CELL TUMORS

  • In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Ozempic® causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined
  • Ozempic® is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Ozempic® and inform them of symptoms of thyroid tumors (eg, a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Ozempic®

Contraindications

  • Ozempic® is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2, and in patients with a hypersensitivity reaction to semaglutide or to any of the excipients in Ozempic®. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with Ozempic®

Warnings and Precautions

  • Risk of Thyroid C-Cell Tumors: Patients should be further evaluated if serum calcitonin is measured and found to be elevated or thyroid nodules are noted on physical examination or neck imaging
  • Acute Pancreatitis: Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, including semaglutide. Observe patients carefully for signs and symptoms of pancreatitis (persistent severe abdominal pain, sometimes radiating to the back with or without vomiting). If pancreatitis is suspected, discontinue Ozempic® and initiate appropriate management
  • Diabetic Retinopathy Complications: In a 2-year trial involving patients with type 2 diabetes and high cardiovascular risk, more events of diabetic retinopathy complications occurred in patients treated with Ozempic® (3.0%) compared with placebo (1.8%). The absolute risk increase for diabetic retinopathy complications was larger among patients with a history of diabetic retinopathy at baseline than among patients without a known history of diabetic retinopathy.
    Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. The effect of long-term glycemic control with semaglutide on diabetic retinopathy complications has not been studied. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy
  • Never Share an Ozempic® Pen Between Patients: Ozempic® pens must never be shared between patients, even if the needle is changed. Pen-sharing poses a risk for transmission of blood-borne pathogens
  • Hypoglycemia: Patients receiving Ozempic® in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. Inform patients using these concomitant medications of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia
  • Acute Kidney Injury Due to Volume Depletion: There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with semaglutide. The majority of reported events occurred in patients who experienced gastrointestinal reactions leading to dehydration such as nausea, vomiting, or diarrhea. Monitor renal function in patients reporting adverse reactions to Ozempic® that could lead to volume depletion, especially during dosage initiation and escalation
  • Severe Gastrointestinal Adverse Reactions: Use of Ozempic® has been associated with gastrointestinal adverse reactions, sometimes severe. In Ozempic® clinical trials, severe gastrointestinal adverse reactions were reported more frequently among patients receiving Ozempic® (0.5 mg 0.4%, 1 mg 0.8%) than placebo (0%). Ozempic® is not recommended in patients with severe gastroparesis
  • Hypersensitivity: Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported in patients treated with Ozempic®. If hypersensitivity reactions occur, discontinue use of Ozempic®; treat promptly per standard of care, and monitor until signs and symptoms resolve. Use caution in a patient with a history of angioedema or anaphylaxis with another GLP-1 receptor agonist
  • Acute Gallbladder Disease: Acute events of gallbladder disease such as cholelithiasis or cholecystitis have been reported in GLP-1 receptor agonist trials and postmarketing. In placebo-controlled trials, cholelithiasis was reported in 1.5% and 0.4% of patients treated with Ozempic® 0.5 mg and 1 mg, respectively, and not reported in placebo-treated patients. If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated
  • Pulmonary Aspiration During General Anesthesia or Deep Sedation: Ozempic® delays gastric emptying. There have been rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations. Instruct patients to inform healthcare providers prior to any planned surgeries or procedures if they are taking Ozempic®

Adverse Reactions

  • The most common adverse reactions, reported in ≥5% of patients treated with Ozempic® are nausea, vomiting, diarrhea, abdominal pain, and constipation

Drug Interactions

  • When initiating Ozempic®, consider reducing the dose of concomitantly administered insulin secretagogue (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia
  • Ozempic® causes a delay of gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications, so caution should be exercised

Use in Specific Populations

  • There are limited data with semaglutide use in pregnant women to inform a drug-associated risk for adverse developmental outcomes. Discontinue Ozempic® in women at least 2 months before a planned pregnancy due to the long washout period for semaglutide

Please click here for Ozempic® Prescribing Information, including Boxed Warning.

Indications and Usage

Ozempic® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg is indicated:

  • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
  • to reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, or nonfatal stroke) in adults with type 2 diabetes and established CV disease
  • to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease

Indications and Usage

Ozempic® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg is indicated:

  • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
  • to reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, or nonfatal stroke) in adults with type 2 diabetes and established CV disease
  • to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease

Important Safety Information for Ozempic®

WARNING: RISK OF THYROID C-CELL TUMORS

  • In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Ozempic® causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined
  • Ozempic® is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Ozempic® and inform them of symptoms of thyroid tumors (eg, a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Ozempic®

Contraindications

  • Ozempic® is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2, and in patients with a hypersensitivity reaction to semaglutide or to any of the excipients in Ozempic®. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with Ozempic®

Warnings and Precautions

  • Risk of Thyroid C-Cell Tumors: Patients should be further evaluated if serum calcitonin is measured and found to be elevated or thyroid nodules are noted on physical examination or neck imaging
  • Acute Pancreatitis: Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, including semaglutide. Observe patients carefully for signs and symptoms of pancreatitis (persistent severe abdominal pain, sometimes radiating to the back with or without vomiting). If pancreatitis is suspected, discontinue Ozempic® and initiate appropriate management
  • Diabetic Retinopathy Complications: In a 2-year trial involving patients with type 2 diabetes and high cardiovascular risk, more events of diabetic retinopathy complications occurred in patients treated with Ozempic® (3.0%) compared with placebo (1.8%). The absolute risk increase for diabetic retinopathy complications was larger among patients with a history of diabetic retinopathy at baseline than among patients without a known history of diabetic retinopathy.
    Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. The effect of long-term glycemic control with semaglutide on diabetic retinopathy complications has not been studied. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy
  • Never Share an Ozempic® Pen Between Patients: Ozempic® pens must never be shared between patients, even if the needle is changed. Pen-sharing poses a risk for transmission of blood-borne pathogens
  • Hypoglycemia: Patients receiving Ozempic® in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. Inform patients using these concomitant medications of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia
  • Acute Kidney Injury Due to Volume Depletion: There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with semaglutide. The majority of reported events occurred in patients who experienced gastrointestinal reactions leading to dehydration such as nausea, vomiting, or diarrhea. Monitor renal function in patients reporting adverse reactions to Ozempic® that could lead to volume depletion, especially during dosage initiation and escalation
  • Severe Gastrointestinal Adverse Reactions: Use of Ozempic® has been associated with gastrointestinal adverse reactions, sometimes severe. In Ozempic® clinical trials, severe gastrointestinal adverse reactions were reported more frequently among patients receiving Ozempic® (0.5 mg 0.4%, 1 mg 0.8%) than placebo (0%). Ozempic® is not recommended in patients with severe gastroparesis
  • Hypersensitivity: Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported in patients treated with Ozempic®. If hypersensitivity reactions occur, discontinue use of Ozempic®; treat promptly per standard of care, and monitor until signs and symptoms resolve. Use caution in a patient with a history of angioedema or anaphylaxis with another GLP-1 receptor agonist
  • Acute Gallbladder Disease: Acute events of gallbladder disease such as cholelithiasis or cholecystitis have been reported in GLP-1 receptor agonist trials and postmarketing. In placebo-controlled trials, cholelithiasis was reported in 1.5% and 0.4% of patients treated with Ozempic® 0.5 mg and 1 mg, respectively, and not reported in placebo-treated patients. If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated
  • Pulmonary Aspiration During General Anesthesia or Deep Sedation: Ozempic® delays gastric emptying. There have been rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations. Instruct patients to inform healthcare providers prior to any planned surgeries or procedures if they are taking Ozempic®

Adverse Reactions

  • The most common adverse reactions, reported in ≥5% of patients treated with Ozempic® are nausea, vomiting, diarrhea, abdominal pain, and constipation

Drug Interactions

  • When initiating Ozempic®, consider reducing the dose of concomitantly administered insulin secretagogue (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia
  • Ozempic® causes a delay of gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications, so caution should be exercised

Use in Specific Populations

  • There are limited data with semaglutide use in pregnant women to inform a drug-associated risk for adverse developmental outcomes. Discontinue Ozempic® in women at least 2 months before a planned pregnancy due to the long washout period for semaglutide

Please click here for Ozempic® Prescribing Information, including Boxed Warning.

Show More Show Less
Show More Show Less

Indications and Usage

Indications and Usage

Ozempic® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg is indicated:

  • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
  • to reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, or nonfatal stroke) in adults with type 2 diabetes and established CV disease
  • to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease

Important Safety Information for Ozempic®

WARNING: RISK OF THYROID C-CELL TUMORS

  • In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Ozempic® causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined
  • Ozempic® is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Ozempic® and inform them of symptoms of thyroid tumors (eg, a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Ozempic®

Important Safety Information for Ozempic®

WARNING: RISK OF THYROID C-CELL TUMORS

  • In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Ozempic® causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined
  • Ozempic® is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Ozempic® and inform them of symptoms of thyroid tumors (eg, a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Ozempic®

Contraindications

  • Ozempic® is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2, and in patients with a hypersensitivity reaction to semaglutide or to any of the excipients in Ozempic®. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with Ozempic®

Warnings and Precautions

  • Risk of Thyroid C-Cell Tumors: Patients should be further evaluated if serum calcitonin is measured and found to be elevated or thyroid nodules are noted on physical examination or neck imaging
  • Acute Pancreatitis: Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, including semaglutide. Observe patients carefully for signs and symptoms of pancreatitis (persistent severe abdominal pain, sometimes radiating to the back with or without vomiting). If pancreatitis is suspected, discontinue Ozempic® and initiate appropriate management
  • Diabetic Retinopathy Complications: In a 2-year trial involving patients with type 2 diabetes and high cardiovascular risk, more events of diabetic retinopathy complications occurred in patients treated with Ozempic® (3.0%) compared with placebo (1.8%). The absolute risk increase for diabetic retinopathy complications was larger among patients with a history of diabetic retinopathy at baseline than among patients without a known history of diabetic retinopathy.
    Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. The effect of long-term glycemic control with semaglutide on diabetic retinopathy complications has not been studied. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy
  • Never Share an Ozempic® Pen Between Patients: Ozempic® pens must never be shared between patients, even if the needle is changed. Pen-sharing poses a risk for transmission of blood-borne pathogens
  • Hypoglycemia: Patients receiving Ozempic® in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. Inform patients using these concomitant medications of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia
  • Acute Kidney Injury Due to Volume Depletion: There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with semaglutide. The majority of reported events occurred in patients who experienced gastrointestinal reactions leading to dehydration such as nausea, vomiting, or diarrhea. Monitor renal function in patients reporting adverse reactions to Ozempic® that could lead to volume depletion, especially during dosage initiation and escalation
  • Severe Gastrointestinal Adverse Reactions: Use of Ozempic® has been associated with gastrointestinal adverse reactions, sometimes severe. In Ozempic® clinical trials, severe gastrointestinal adverse reactions were reported more frequently among patients receiving Ozempic® (0.5 mg 0.4%, 1 mg 0.8%) than placebo (0%). Ozempic® is not recommended in patients with severe gastroparesis
  • Hypersensitivity: Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported in patients treated with Ozempic®. If hypersensitivity reactions occur, discontinue use of Ozempic®; treat promptly per standard of care, and monitor until signs and symptoms resolve. Use caution in a patient with a history of angioedema or anaphylaxis with another GLP-1 receptor agonist
  • Acute Gallbladder Disease: Acute events of gallbladder disease such as cholelithiasis or cholecystitis have been reported in GLP-1 receptor agonist trials and postmarketing. In placebo-controlled trials, cholelithiasis was reported in 1.5% and 0.4% of patients treated with Ozempic® 0.5 mg and 1 mg, respectively, and not reported in placebo-treated patients. If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated
  • Pulmonary Aspiration During General Anesthesia or Deep Sedation: Ozempic® delays gastric emptying. There have been rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations. Instruct patients to inform healthcare providers prior to any planned surgeries or procedures if they are taking Ozempic®

Adverse Reactions

  • The most common adverse reactions, reported in ≥5% of patients treated with Ozempic® are nausea, vomiting, diarrhea, abdominal pain, and constipation

Drug Interactions

  • When initiating Ozempic®, consider reducing the dose of concomitantly administered insulin secretagogue (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia
  • Ozempic® causes a delay of gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications, so caution should be exercised

Use in Specific Populations

  • There are limited data with semaglutide use in pregnant women to inform a drug-associated risk for adverse developmental outcomes. Discontinue Ozempic® in women at least 2 months before a planned pregnancy due to the long washout period for semaglutide

Please click here for Ozempic® Prescribing Information, including Boxed Warning.

Important Safety Information for Ozempic®

WARNING: RISK OF THYROID C-CELL TUMORS

  • In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Ozempic® causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined
  • Ozempic® is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Ozempic® and inform them of symptoms of thyroid tumors (eg, a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Ozempic®

Contraindications

  • Ozempic® is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2, and in patients with a hypersensitivity reaction to semaglutide or to any of the excipients in Ozempic®. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with Ozempic®

Warnings and Precautions

  • Risk of Thyroid C-Cell Tumors: Patients should be further evaluated if serum calcitonin is measured and found to be elevated or thyroid nodules are noted on physical examination or neck imaging
  • Acute Pancreatitis: Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, including semaglutide. Observe patients carefully for signs and symptoms of pancreatitis (persistent severe abdominal pain, sometimes radiating to the back with or without vomiting). If pancreatitis is suspected, discontinue Ozempic® and initiate appropriate management
  • Diabetic Retinopathy Complications: In a 2-year trial involving patients with type 2 diabetes and high cardiovascular risk, more events of diabetic retinopathy complications occurred in patients treated with Ozempic® (3.0%) compared with placebo (1.8%). The absolute risk increase for diabetic retinopathy complications was larger among patients with a history of diabetic retinopathy at baseline than among patients without a known history of diabetic retinopathy.
    Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. The effect of long-term glycemic control with semaglutide on diabetic retinopathy complications has not been studied. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy
  • Never Share an Ozempic® Pen Between Patients: Ozempic® pens must never be shared between patients, even if the needle is changed. Pen-sharing poses a risk for transmission of blood-borne pathogens
  • Hypoglycemia: Patients receiving Ozempic® in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. Inform patients using these concomitant medications of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia
  • Acute Kidney Injury Due to Volume Depletion: There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with semaglutide. The majority of reported events occurred in patients who experienced gastrointestinal reactions leading to dehydration such as nausea, vomiting, or diarrhea. Monitor renal function in patients reporting adverse reactions to Ozempic® that could lead to volume depletion, especially during dosage initiation and escalation
  • Severe Gastrointestinal Adverse Reactions: Use of Ozempic® has been associated with gastrointestinal adverse reactions, sometimes severe. In Ozempic® clinical trials, severe gastrointestinal adverse reactions were reported more frequently among patients receiving Ozempic® (0.5 mg 0.4%, 1 mg 0.8%) than placebo (0%). Ozempic® is not recommended in patients with severe gastroparesis
  • Hypersensitivity: Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported in patients treated with Ozempic®. If hypersensitivity reactions occur, discontinue use of Ozempic®; treat promptly per standard of care, and monitor until signs and symptoms resolve. Use caution in a patient with a history of angioedema or anaphylaxis with another GLP-1 receptor agonist
  • Acute Gallbladder Disease: Acute events of gallbladder disease such as cholelithiasis or cholecystitis have been reported in GLP-1 receptor agonist trials and postmarketing. In placebo-controlled trials, cholelithiasis was reported in 1.5% and 0.4% of patients treated with Ozempic® 0.5 mg and 1 mg, respectively, and not reported in placebo-treated patients. If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated
  • Pulmonary Aspiration During General Anesthesia or Deep Sedation: Ozempic® delays gastric emptying. There have been rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations. Instruct patients to inform healthcare providers prior to any planned surgeries or procedures if they are taking Ozempic®

Adverse Reactions

  • The most common adverse reactions, reported in ≥5% of patients treated with Ozempic® are nausea, vomiting, diarrhea, abdominal pain, and constipation

Drug Interactions

  • When initiating Ozempic®, consider reducing the dose of concomitantly administered insulin secretagogue (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia
  • Ozempic® causes a delay of gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications, so caution should be exercised

Use in Specific Populations

  • There are limited data with semaglutide use in pregnant women to inform a drug-associated risk for adverse developmental outcomes. Discontinue Ozempic® in women at least 2 months before a planned pregnancy due to the long washout period for semaglutide

Please click here for Ozempic® Prescribing Information, including Boxed Warning.

Indications and Usage

Ozempic® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg is indicated:

  • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
  • to reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, or nonfatal stroke) in adults with type 2 diabetes and established CV disease
  • to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease

Indications and Usage

Ozempic® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg is indicated:

  • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
  • to reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, or nonfatal stroke) in adults with type 2 diabetes and established CV disease
  • to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease

Important Safety Information for Ozempic®

WARNING: RISK OF THYROID C-CELL TUMORS

  • In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Ozempic® causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined
  • Ozempic® is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Ozempic® and inform them of symptoms of thyroid tumors (eg, a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Ozempic®

Contraindications

  • Ozempic® is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2, and in patients with a hypersensitivity reaction to semaglutide or to any of the excipients in Ozempic®. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with Ozempic®

Warnings and Precautions

  • Risk of Thyroid C-Cell Tumors: Patients should be further evaluated if serum calcitonin is measured and found to be elevated or thyroid nodules are noted on physical examination or neck imaging
  • Acute Pancreatitis: Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, including semaglutide. Observe patients carefully for signs and symptoms of pancreatitis (persistent severe abdominal pain, sometimes radiating to the back with or without vomiting). If pancreatitis is suspected, discontinue Ozempic® and initiate appropriate management
  • Diabetic Retinopathy Complications: In a 2-year trial involving patients with type 2 diabetes and high cardiovascular risk, more events of diabetic retinopathy complications occurred in patients treated with Ozempic® (3.0%) compared with placebo (1.8%). The absolute risk increase for diabetic retinopathy complications was larger among patients with a history of diabetic retinopathy at baseline than among patients without a known history of diabetic retinopathy.
    Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. The effect of long-term glycemic control with semaglutide on diabetic retinopathy complications has not been studied. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy
  • Never Share an Ozempic® Pen Between Patients: Ozempic® pens must never be shared between patients, even if the needle is changed. Pen-sharing poses a risk for transmission of blood-borne pathogens
  • Hypoglycemia: Patients receiving Ozempic® in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. Inform patients using these concomitant medications of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia
  • Acute Kidney Injury Due to Volume Depletion: There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with semaglutide. The majority of reported events occurred in patients who experienced gastrointestinal reactions leading to dehydration such as nausea, vomiting, or diarrhea. Monitor renal function in patients reporting adverse reactions to Ozempic® that could lead to volume depletion, especially during dosage initiation and escalation
  • Severe Gastrointestinal Adverse Reactions: Use of Ozempic® has been associated with gastrointestinal adverse reactions, sometimes severe. In Ozempic® clinical trials, severe gastrointestinal adverse reactions were reported more frequently among patients receiving Ozempic® (0.5 mg 0.4%, 1 mg 0.8%) than placebo (0%). Ozempic® is not recommended in patients with severe gastroparesis
  • Hypersensitivity: Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported in patients treated with Ozempic®. If hypersensitivity reactions occur, discontinue use of Ozempic®; treat promptly per standard of care, and monitor until signs and symptoms resolve. Use caution in a patient with a history of angioedema or anaphylaxis with another GLP-1 receptor agonist
  • Acute Gallbladder Disease: Acute events of gallbladder disease such as cholelithiasis or cholecystitis have been reported in GLP-1 receptor agonist trials and postmarketing. In placebo-controlled trials, cholelithiasis was reported in 1.5% and 0.4% of patients treated with Ozempic® 0.5 mg and 1 mg, respectively, and not reported in placebo-treated patients. If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated
  • Pulmonary Aspiration During General Anesthesia or Deep Sedation: Ozempic® delays gastric emptying. There have been rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations. Instruct patients to inform healthcare providers prior to any planned surgeries or procedures if they are taking Ozempic®

Adverse Reactions

  • The most common adverse reactions, reported in ≥5% of patients treated with Ozempic® are nausea, vomiting, diarrhea, abdominal pain, and constipation

Drug Interactions

  • When initiating Ozempic®, consider reducing the dose of concomitantly administered insulin secretagogue (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia
  • Ozempic® causes a delay of gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications, so caution should be exercised

Use in Specific Populations

  • There are limited data with semaglutide use in pregnant women to inform a drug-associated risk for adverse developmental outcomes. Discontinue Ozempic® in women at least 2 months before a planned pregnancy due to the long washout period for semaglutide

Please click here for Ozempic® Prescribing Information, including Boxed Warning.

Reference:

  1. Ozempic® [package insert]. Plainsboro, NJ: Novo Nordisk Inc.
For Health Care Professionals
  • Diabetes Home
  • Product Information
    Products
    • Diabetes Treatments
    Professional Resources
    • Product Resources Library
      Insulin & Type 1 Diabetes
  • Sample Requests
  • Professional Education
    Diabetes Education
    • Clinical Education Library
      Diabetes Risk Assessment Tool
      Diabetes & Cardiovascular Disease
    Treatment Guidelines
    • ADA Standards of Care
      AACE Diabetes Guidelines
    Additional Resources
    • Organizations & Conferences
  • Patient Support
    Product Education
    • Product Education Materials
      Pen Device Training Center
    Disease Education
    • Disease Education Library
    Prescription Savings & Coverage
    • Savings Cards
      Insurance Coverage
      Affordability Resources
      ICD-10 Codes for Diabetes
    Support Program
    • Diabetes Management
      Cardiovascular Risk Management

Ozempic® is a registered trademark and novoMEDLINK™ is a trademark of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
All other trademarks, registered or unregistered, are the property of their respective owners.
Non-US Health Care Professionals, please go to www.novonordiskpro.com.

Terms of Use | Privacy Notice | Consumer Health Privacy Notice | Cookie Notice | Privacy Request | Contact Us |
novonordisk-us.com    
© 2025 Novo Nordisk All rights reserved. US25OZM00476 May 2025

What can we help you do today?

Quick links

Request medication samples

Diabetes treatment guidelines

Patient savings card offer

Patient support program

Medical Information     |     Non-US Health Care Professionals